帐号 注册
密码 登录
登录或注册新用户,开通自己的个人中心
回复 6楼心中充满爱的帖子您那不是相信科学,而是不敢坦然面对事实,是迷信科学.坦然...... PZWPZW 发表于 2013/2/6 13:57:00
[quote]回复 6楼心中充满爱的帖子您那不是相信科学,而是不敢坦然面对事实,是迷信科......心中充满爱 发表于 2013/2/7 15:43:00 好,听心中充满爱的话,虫虫不咬jj.我来试译一下<摘要>,请战友们斧正:Abstract(摘要)The best hope of controlling the herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) pandemic is the development of an effective vaccine(防止疱疹扩散的最好愿望是开发出有效的疫苗). However, in spite of several clinical trials, starting as early as 1920s, no vaccine has been proven sufficiently safe and efficient to warrant commercial development(然而,从上世纪20年代开始,经过多次临床试验,并没有什么疫苗被证明是足够安全和有效的,无法投入商业量产). In recent years, great strides in cellular and molecular immunology have stimulated creative efforts in controlling herpes infection and disease(近年来,细胞免疫学和分子免疫学领域的巨大突破,刺激着人们在PP感染和疾病控制方面做出了创造性的努力尝试). However, before moving towards new vaccine strategy, it is necessary to answer two fundamental questions(在我们探求疫苗开发思路之前,我们首先要回答2个基本的问题): (i) why past herpes vaccines have failed?(前人为什么失败?) (ii) Why the majority of HSV seropositive individuals (i.e., asymptomatic individuals) are naturally “protected” exhibiting few or no recurrent clinical disease, while other HSV seropositive individuals (i.e., symptomatic individuals) have frequent ocular, orofacial, and/or genital herpes clinical episodes?(同样血清阳性为什么大部分人没有症状?) We recently discovered several discrete sets of HSV-1 symptomatic and asymptomatic epitopes recognized by CD4+ and CD8+ T cells from seropositive symptomatic versus asymptomatic individuals. These asymptomatic epitopes will provide a solid foundation for the development of novel herpes epitope-based vaccine strategy. Here we provide a brief overview of past clinical vaccine trials, outline current progress towards developing a new generation “asymptomatic” clinical herpes vaccines, and discuss future mucosal “asymptomatic” prime-boost vaccines that could optimize local protective immunity.(这一段技术术语较多,汉语一句话:他想从那些健康带毒者身上找到免疫的奥秘)
The best hope of controlling the herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) pandemic is the development of an effective vaccine(防止疱疹扩散的最好愿望是开发出有效的疫苗). However, in spite of several clinical trials, starting as early as 1920s, no vaccine has been proven sufficiently safe and efficient to warrant commercial development(然而,从上世纪20年代开始,经过多次临床试验,并没有什么疫苗被证明是足够安全和有效的,无法投入商业量产). In recent years, great strides in cellular and molecular immunology have stimulated creative efforts in controlling herpes infection and disease(近年来,细胞免疫学和分子免疫学领域的巨大突破,刺激着人们在PP感染和疾病控制方面做出了创造性的努力尝试). However, before moving towards new vaccine strategy, it is necessary to answer two fundamental questions(在我们探求疫苗开发思路之前,我们首先要回答2个基本的问题): (i) why past herpes vaccines have failed?(前人为什么失败?) (ii) Why the majority of HSV seropositive individuals (i.e., asymptomatic individuals) are naturally “protected” exhibiting few or no recurrent clinical disease, while other HSV seropositive individuals (i.e., symptomatic individuals) have frequent ocular, orofacial, and/or genital herpes clinical episodes?(同样血清阳性为什么大部分人没有症状?) We recently discovered several discrete sets of HSV-1 symptomatic and asymptomatic epitopes recognized by CD4+ and CD8+ T cells from seropositive symptomatic versus asymptomatic individuals. These asymptomatic epitopes will provide a solid foundation for the development of novel herpes epitope-based vaccine strategy. Here we provide a brief overview of past clinical vaccine trials, outline current progress towards developing a new generation “asymptomatic” clinical herpes vaccines, and discuss future mucosal “asymptomatic” prime-boost vaccines that could optimize local protective immunity.(这一段技术术语较多,汉语一句话:他想从那些健康带毒者身上找到免疫的奥秘)
